Results 21 to 30 of about 12,417 (199)

Tenecteplase versus alteplase in patients with acute ischemic stroke: an updated systematic review and meta-analysis [PDF]

European Journal of Medical Research
Background Stroke was the second leading cause of death and the third leading cause of disability worldwide in 2019. Alteplase is an FDA-approved medication for the treatment of patients with ischemic stroke within 4.5 h.
Abdelmonam M. Hagag, Muhammed E. Kormod, Mahmoud Elmwafy Ads, Mennatullah A. El-Refaay, Omnia M. Abozaid, Omar A. Ghanem, Mazen Yasser, Karim M. Abdelmoaty, Alaa Mahmoud Khedr, Gregory W. Albers   +9 more
doaj   +2 more sources

Effectiveness of alteplase in the very elderly after acute ischemic stroke

Clinical Interventions in Aging, 2013
Josef Yayan Department of Internal Medicine, University Hospital of Saarland, Homburg/Saar, Germany Abstract: Alteplase has traditionally been the only pharmacologic agent available for treating acute ischemic stroke worldwide, and is considered an ...
Yayan J
doaj   +1 more source

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials [PDF]

Lancet, The, 2014
Jonathan R Emberson, Patrick Lyden, Gregory Albers   +2 more
exaly   +2 more sources

Low-dose vs. standard-dose alteplase for Chinese patients with acute ischemic stroke: A propensity score analysis

Frontiers in Neurology, 2023
Background and purposePrevious studies have stimulated debates on low-dose alteplase administration in acute ischemic stroke (AIS) among the Asian population.
Jiawen Xu, Xi Chen, Yanan Xie, Yi Wang, Shidong Chen, Qiang Dong, Yi Dong, Kun Fang   +7 more
doaj   +1 more source

Outcomes and Treatment Complications of Intravenous Urokinase Thrombolysis in Acute Ischemic Stroke in China

Frontiers in Neurology, 2021
Background: Intravenous thrombolysis with alteplase benefits eligible patients with acute ischemic stroke. However, in some countries such as China, alteplase may be too expensive for low-income patients, and also for regions with low economic ...
Rongrong Zhang, Hui Wei, Yu Ren, Yanping Wu, Yetao Luo, Lei Zhang, Yingchao Huo, Jinzhou Feng, Philippe P. Monnier, Philippe P. Monnier, Philippe P. Monnier, Xinyue Qin   +11 more
doaj   +1 more source

Tenecteplase Thrombolysis in Posterior Circulation Stroke

Frontiers in Neurology, 2021
One in five ischaemic strokes affects the posterior circulation. Basilar artery occlusion is a type of posterior circulation stroke associated with a high risk of disability and mortality.
Fana Alemseged, Bruce C. V. Campbell
doaj   +1 more source

A comparison of low- versus standard-dose bridging alteplase in acute ischemic stroke mechanical thrombectomy using indirect methods

Therapeutic Advances in Neurological Disorders, 2023
Background: Whether low-dose alteplase is similar to standard-dose bridging alteplase prior to endovascular mechanical thrombectomy in patients with acute ischemic stroke (AIS) remains uncertain.
Wei Zheng, Hanhan Lei, Gareth Ambler, David J. Werring, Huiying Lin, Xiaojuan Lin, Yi Tang, Jing Wu, Zhaomin Lin, Nan Liu, Houwei Du   +10 more
doaj   +1 more source

Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?

Western Journal of Emergency Medicine, 2020
Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as ...
Tony Zitek, Ramsey Ataya, Isabel Brea
doaj   +1 more source

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials

Frontiers in Neurology, 2023
BackgroundThe optimal dose of tenecteplase vs. alteplase for acute ischemic stroke (AIS) has yet to be established. Therefore, we included the latest randomized controlled trials (RCT) to assess the efficacy and safety of different doses of tenecteplase ...
Huo Liang, Xue Wang, Xuemei Quan, Shijian Chen, Bin Qin, Shuolin Liang, Qiuhui Huang, Jian Zhang, Zhijian Liang   +8 more
doaj   +1 more source

Use of carefully titrated ultra‐low doses of alteplase in infected haemothorax caused by initial alteplase use to drain loculated malignant pleural effusion

Respirology Case Reports, 2023
Alteplase as a fibrinolytic can be used to break up fibrin to encourage clot breakdown for clinical use. In the pleural space, it is used for symptomatic loculated malignant pleural effusions and pleural infections and can potentially avoid the need for ...
Jeong Suk Oh, Chris Yoo, Donny Wong
doaj   +1 more source